Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and fenofibrate crossover study in type 2 diabetes with hyperuricaemia
ACTRN12621000829819Phase 4Not yet recruiting
- Sponsor
- Timothy Davis
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of empagliflozin and fenofibrate in hyperuricemia (3 arms), sponsored by Timothy Davis. Primary endpoint: Change in fasting serum uric acid. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
empagliflozinfenofibrate
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on ACTRN12621000829819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000829819.